Cyclacel Pharmaceuticals (CYCC) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

CYCC Stock Forecast


Cyclacel Pharmaceuticals (CYCC) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $1.00, with a high of $1.00 and a low of $1.00. This represents a -84.30% decline from the last price of $6.37.

- $1 $2 $3 $4 $5 $6 $7 High: $1 Avg: $1 Low: $1 Last Closed Price: $6.37

CYCC Stock Rating


Cyclacel Pharmaceuticals stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (71.43%), 2 Hold (28.57%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 2 5 Strong Sell Sell Hold Buy Strong Buy

CYCC Price Target Upside V Benchmarks


TypeNameUpside
StockCyclacel Pharmaceuticals-84.30%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$6.37$6.37$6.37
Upside/Downside---
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25--1--1
Jan, 25--1--1
Dec, 24--1--1
Nov, 24-11--2
Oct, 24111--3
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 23, 2024Jonathan AschoffRoth Capital$1.00$1.14-12.28%-84.30%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Mar 07, 2023OppenheimerOutperformOutperformhold

Financial Forecast


EPS Forecast

$-30 $-22 $-14 $-6 $2 $10 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-28.67$-1.36$-6.45---
Avg Forecast$-20.23$-1.95$-1.18$-1.12$3.67$5.49
High Forecast$-19.70$-1.95$-1.18$-1.12$3.67$5.49
Low Forecast$-20.75$-1.95$-1.18$-1.12$3.67$5.49
Surprise %41.72%-30.26%446.61%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$420.00K$43.00K$747.00K---
Avg Forecast$263.00K$53.00K$100.00K$100.00K$80.58M$118.08M
High Forecast$263.00K$53.00K$100.00K$100.00K$80.58M$118.08M
Low Forecast$263.00K$53.00K$100.00K$100.00K$80.58M$118.08M
Surprise %59.70%-18.87%647.00%---

Net Income Forecast

$-25M $-19M $-13M $-7M $-1M $5M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-22.55M$-11.21M$-3.00M---
Avg Forecast$-17.21M$-1.66M$-1.00M$-952.91K$3.12M$4.67M
High Forecast$-16.76M$-1.66M$-1.00M$-952.91K$3.12M$4.67M
Low Forecast$-17.65M$-1.66M$-1.00M$-952.91K$3.12M$4.67M
Surprise %31.09%575.79%198.62%---

CYCC Forecast FAQ


Is Cyclacel Pharmaceuticals stock a buy?

Cyclacel Pharmaceuticals stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cyclacel Pharmaceuticals is a favorable investment for most analysts.

What is Cyclacel Pharmaceuticals's price target?

Cyclacel Pharmaceuticals's price target, set by 7 Wall Street analysts, averages $1 over the next 12 months. The price target range spans from $1 at the low end to $1 at the high end, suggesting a potential -84.30% change from the previous closing price of $6.37.

How does Cyclacel Pharmaceuticals stock forecast compare to its benchmarks?

Cyclacel Pharmaceuticals's stock forecast shows a -84.30% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Cyclacel Pharmaceuticals over the past three months?

  • February 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Cyclacel Pharmaceuticals’s EPS forecast?

Cyclacel Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.12, marking a -82.64% decrease from the reported $-6.45 in 2025. Estimates for the following years are $3.67 in 2027, and $5.49 in 2028.

What is Cyclacel Pharmaceuticals’s revenue forecast?

Cyclacel Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $100K, reflecting a -86.61% decrease from the reported $747K in 2025. The forecast for 2027 is $80.58M, and $118.08M for 2028.

What is Cyclacel Pharmaceuticals’s net income forecast?

Cyclacel Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-953K, representing a -68.22% decrease from the reported $-2.998M in 2025. Projections indicate $3.12M in 2027, and $4.67M in 2028.